Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01521559 · ClinicalTrials.gov registry record · Phase 3

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

A Phase 3 study of Branch Retinal Vein Occlusion, sponsored by Regeneron Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
183
Enrollment target
20
Study locations

NCT01521559 is a Phase 3 study of Branch Retinal Vein Occlusion that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 183 participants, below the 2,011-participant average among 3 other Branch Retinal Vein Occlusion trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01521559, a Phase 3 study of Branch Retinal Vein Occlusion, has completed, sponsored by Regeneron Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
183 participants
Enrollment target
20
Study locations

Study Summary

This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in patients with macular edema secondary to BRVO.

Conditions Studied

Branch Retinal Vein Occlusion

Interventions

  • PROCEDURE Macular Laser Photocoagulation
  • DRUG Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)

Study Locations (20)

Florida

  • - Fort Myers
  • - Miami
  • - Plantation
  • - Stuart
  • - Tampa
  • - Winter Haven

California

  • - Beverly Hills
  • - La Jolla
  • - Mountain View
  • - Palm Desert
  • - Sacramento

Arizona

  • - Phoenix
  • - Tucson

Maryland

  • - Baltimore (2 Locations)
  • - Hagerstown

Colorado

  • - Colorado Springs

Georgia

  • - Augusta

Illinois

  • - Chicago

Massachusetts

  • - Boston (2 Locations)

Trial Details

FieldValue
Enrollment Target 183 participants
Start Date 2012-04
Est. Completion 2014-03
Phase Phase 3

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01521559

The ClinicalTrials.gov registry entry for NCT01521559 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,011-participant average among 3 other Branch Retinal Vein Occlusion trials with a reported enrollment target (91% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Branch Retinal Vein Occlusion appearing as the primary indexed condition, and to 2 interventions - of which Macular Laser Photocoagulation is the first listed.

NCT01521559 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT01521559 about?

NCT01521559 is a clinical study titled "Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)". This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in patients with macular edema secondary to BRVO.

What is the current status of trial NCT01521559?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 183 participants. The study started on 2012-04. Estimated completion is 2014-03.

What conditions does trial NCT01521559 study?

This clinical trial studies the following conditions: Branch Retinal Vein Occlusion.

What interventions are being tested in trial NCT01521559?

The interventions under investigation include: Macular Laser Photocoagulation (PROCEDURE), Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) (DRUG).

Who is sponsoring clinical trial NCT01521559?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01521559 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Branch Retinal Vein Occlusion

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Branch Retinal Vein Occlusion

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.